Related Experiment Video
Updated: May 23, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
The Effect of COVID-19 on Type 1 Diabetes Occurrence among Children and Adolescents: A Multicenter Prospective
Noah Gruber1,2, Liat Brand1,2, Ehud Barhod3
1Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Insights
This study found no link between SARS-CoV-2 infection and new-onset type 1 diabetes (T1D) in children. Further research is needed to understand long-term effects of the pandemic on pediatric T1D incidence.
Area of Science:
- Pediatric Endocrinology
- Infectious Diseases
- Immunology
Background:
- The relationship between SARS-CoV-2 infection and type 1 diabetes (T1D) in children remains unclear.
- Investigating potential links between viral infections and autoimmune diseases like T1D is crucial.
Purpose of the Study:
- To determine if there is an association between SARS-CoV-2 infection seroprevalence and the occurrence of T1D in pediatric populations.
- To analyze distinct anti-SARS-CoV-2 antibody responses in children with new-onset T1D compared to a control group.
Main Methods:
- A multicenter prospective observational cohort study involving children with new-onset T1D and a control group (1:3 ratio).
- Assessment of anti-SARS-CoV-2 antibodies (anti-S, anti-N, neutralizing antibodies) in both groups.
- Comparison of antibody seroprevalence and association with glycemic parameters and diabetic ketoacidosis (DKA).
Main Results:
- No increased seroprevalence of anti-SARS-CoV-2 antibodies was found in children with new-onset T1D compared to controls.
- A higher anti-S seroprevalence was observed in T1D patients without DKA, but this was not statistically significant after adjusting for vaccination status.
- No significant differences in anti-N or neutralizing antibodies were found between DKA and non-DKA groups, nor were antibodies associated with glycemic parameters.
Conclusions:
- Current findings do not support a direct association between SARS-CoV-2 infection and the incidence of T1D in children and adolescents.
- Longitudinal epidemiological studies are recommended to evaluate potential delayed autoimmune responses and changes in T1D incidence post-pandemic.
Aim:
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the pediatric occurrence of type 1 diabetes (T1D) is inconclusive. We aimed to assess associations between seroprevalences of the distinct anti-SARS-CoV-2 antibodies and T1D occurrence in children and adolescents.
Methods:
This multicenter prospective observational cohort comprised children diagnosed with T1D between October 2020 and July 2022 and unrelated children who performed endocrine tests (control group) in a 1 : 3 ratio. Anti-SARS-CoV-2 antibodies, including anti-S, anti-N, and neutralizing antibodies, were assessed in each group.
Results:
The cohort included 51 children with T1D and 182 children in the control group. The median (interquartile range) age was 11.4 (8.2, 13.3) years, with 45% being female. Increases were not observed in the seroprevalence of any of the anti-SARS-CoV-2 antibodies among the children with new-onset T1D compared to the control group. Among the T1D group, anti-S seroprevalence was higher among those without diabetic ketoacidosis (DKA) than in those with DKA upon T1D diagnosis (72% vs. 42%, p=0.035). After adjustment to vaccination status, this difference was not statistically significant. Additionally, anti-N antibodies and neutralizing antibodies did not differ between the DKA and the non-DKA groups. None of the anti-SARS-CoV-2 antibodies were associated with any of the glycemic parameters.
Conclusions:
This study is the first to assess several distinct anti-SARS-CoV-2 antibodies in new-onset T1D, and our findings do not support an association between SARS-CoV-2 infection and the occurrence of T1D in children and adolescents. Since autoimmunity may emerge years after a viral infection, we recommend conducting follow-up epidemiological studies to assess whether there is a change in the incidence of T1D following the SARS-CoV-2 pandemic.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Psychoneuroimmunology: Diabetes and Cancer

